<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351740</url>
  </required_header>
  <id_info>
    <org_study_id>H10-03255</org_study_id>
    <secondary_id>H10-03255</secondary_id>
    <nct_id>NCT01351740</nct_id>
  </id_info>
  <brief_title>Switch to Unboosted Atazanavir With Tenofovir Study</brief_title>
  <acronym>SUAT</acronym>
  <official_title>Switch to Unboosted Atazanavir With Tenofovir (SUAT) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A drug-drug interaction between the anti-HIV drugs tenofovir DF (TDF) and atazanavir (ATZ)
      results in lower ATZ plasma levels when the drugs are given together, particularly in
      patients not taking ritonavir to boost ATZ levels. Lower plasma drug levels may make the
      anti-HIV regimen less effective in controlling the HIV virus levels in the blood. For this
      reason, current treatment guidelines recommend that ATZ always be boosted with ritonavir in
      regimens also containing TDF. However, withdrawal of ritonavir is often desirable given the
      tolerability and toxicity issues with this agent, even at the low dose (100 mg daily) used to
      boost ATZ. For example, ritonavir can cause stomach upset, nausea, diarrhea, high cholesterol
      levels, and liver enzyme abnormalities.

      However, there is evidence that plasma ATZ levels may not predict treatment success on
      unboosted ATZ regimens, particularly among people whose plasma HIV virus is already under
      control and unboosted ATZ is being used as a maintenance strategy. In the BC Centre for
      Excellence in HIV/AIDS Drug Treatment Program (DTP), nearly 100 patients originally treated
      with ritonavir-boosted ATZ + TDF (+ FTC or 3TC) are receiving successful maintenance therapy
      with unboosted ATZ and the same TDF-based backbone.

      The study will examine the hypothesis that switching to maintenance therapy with unboosted
      ATZ 400mg daily will have similar 48-week virologic efficacy to continuing ATZ/ritonavir
      300/100mg daily among HIV-infected adults with stable viral load suppression on regimens
      comprising ATZ/ritonavir 300/100mg daily with TDF plus either FTC or 3TC, despite potentially
      lower ATZ trough levels with the unboosted regimen. In other words, patients whose HIV viral
      load is undetectable while receiving TDF (+FTC or 3TC) and ATZ/ritonavir will continue to
      maintain an undetectable viral load after switching to unboosted ATZ without ritonavir, in
      the same proportions as those continuing on their boosted ATZ/ritonavir regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a screening visit to establish study eligibility, eligible consenting subjects will
      be randomized 1:1 to one of the two treatment arms (switch to unboosted ATZ or continue
      ritonavir-boosted ATZ). Randomized open-label treatment will commence following study
      procedures at baseline. Participants will be assessed at baseline and at weeks 4, 8, 12, 24,
      36, and 48. On-study evaluations will include assessment of adverse clinical events and
      medication changes; blood tests for HIV viral load, CD4 cell count, standard safety
      parameters, fasting lipids and glucose, and pregnancy testing (if applicable); and urine
      tests for urinalysis and albumin to creatinine ratio. In addition, a serum sample will be
      stored at each visit for possible future testing. A timed plasma sample for measurement of
      pre-dose trough ATZ levels will be obtained once per subject at 4-8 weeks. Quality of life
      will be assessed by completion of the MOS-HIV questionnaire at baseline and every 12 weeks.
      Adherence will be assessed based on prescription refill data.

      In case of protocol-defined virologic failure, a plasma sample for ATZ trough level will be
      collected, and genotypic resistance testing will be performed on plasma samples with viral
      load &gt;250 copies/mL. Subjects with confirmed virologic failure will be asked to come to the
      clinic and will have their HIV treatment changed to a more effective regimen, selected based
      on the results of genotypic testing, as soon as possible.

      The anticipated rate of confirmed virologic failure in the control arm is no more than 15%
      over the 48 weeks of the study. Once at least 20 subjects have been assigned to the
      experimental (switch) treatment arm, if the observed confirmed virologic failure rate in the
      experimental arm is greater than twice this rate, i.e. &gt;30%, at any time during the study,
      the study will be stopped. At this time, subjects in the experimental arm will be reassessed
      as soon as possible and will resume ritonavir-boosted atazanavir or other effective HIV
      therapy as appropriate. The failure rate will be reassessed at a minimum after each 20
      subjects are enrolled into the experimental (switch) arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of Subjects Experiencing Virologic Failure by Randomized Treatment Arm</measure>
    <time_frame>at or before 48 weeks.</time_frame>
    <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportions of Subjects in Each Randomized Treatment Arm With Atazanavir Trough Levels Below 150ng/mL</measure>
    <time_frame>1 month (4-8 weeks)</time_frame>
    <description>Therapeutic drug monitoring (TDM) to determine atazanavir trough plasma level will be performed once on all subjects at 4-8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Experiencing Virologic Failure by Results of 1-month TDM</measure>
    <time_frame>at or before 48 weeks</time_frame>
    <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart. Comparison will be made between subjects with 1-month (4-8 week) on-study atazanavir trough levels &lt;150ng/mL and those with 1-month (4-8 week) on-study atazanavir trough levels &gt;150ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Subjects Experiencing Virologic Failure by Randomized Treatment Arm</measure>
    <time_frame>at or before 24 weeks.</time_frame>
    <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Experiencing Virologic Failure by Results of 1-month TDM</measure>
    <time_frame>at or before 24 weeks</time_frame>
    <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart. Comparison will be made between subjects with 1-month (4-8 week) on-study atazanavir trough levels &lt;150ng/mL and those with 1-month (4-8 week) on-study atazanavir trough levels &gt;150ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Cell Count Changes (Absolute and Fraction)</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Comparison will be made between randomized treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Clinical and Laboratory Adverse Events)</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Serious adverse events and discontinuations will be compared between randomized treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Serum Bilirubin Levels</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Comparison will be made between randomized treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Parameters</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Comparison will be made between randomized treatment arms with respect to changes in fasting lipids and glucose, highly sensitive C-reactive protein [hsCRP], and apolipoprotein [apo]B, and proportions of subjects developing abnormalities or crossing predefined limits (e.g. NCEP thresholds for lipids)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Assessed by MOS-HIV</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Changes in MOS-HIV scores from baseline will be compared between randomized treatment arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Switch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>switch to unboosted atazanavir 400mg daily with the same nucleoside (NRTI) backbone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>continue on current regimen of atazanavir/ritonavir 300mg/100mg with the same nucleoside (NRTI) backbone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir</intervention_name>
    <description>switch to unboosted atazanavir 400 mg daily</description>
    <arm_group_label>Switch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir/ritonavir</intervention_name>
    <description>Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily</description>
    <arm_group_label>Continuation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV infected adults at least 19 years of age

          2. Willing and able to provide informed consent to study participation

          3. Currently receiving a regimen including atazanavir 300mg/ritonavir 100mg daily with
             either tenofovir/emtricitabine (FTC) or tenofovir/lamivudine (3TC), for at least 3
             months

          4. Plasma viral load (VL) &lt;40 copies/mL for at least 2 consecutive measurements including
             the screening value, and &lt; 150 copies/mL continuously for at least 3 months prior to
             screening

          5. Current regimen is first antiretroviral regimen, or if not first regimen, no evidence
             of resistance to any nucleosides (NRTIs) or protease inhibitors (PIs) on previous
             resistance tests

          6. Any CD4

        Exclusion Criteria:

          1. Clinically significant intolerance or toxicity with current regimen precluding regimen
             continuation (e.g. intolerance/toxicity to ritonavir necessitating ritonavir
             discontinuation)

          2. pregnancy or breast-feeding

          3. antiretroviral regimen including any nonnucleoside reverse transcriptase inhibitor
             (nevirapine, efavirenz, or etravirine)

          4. antiretroviral regimen including any protease inhibitor other than atazanavir and
             ritonavir

          5. concomitant treatment with proton pump inhibitors, rifampin, St. John's wort, or
             garlic supplements. (Antacids and H2 receptor antagonists will be allowed provided
             their dosing is separated from atazanavir administration by at least 2 and 10 hours,
             respectively).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Harris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Health Care/ University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Immunodeficiency Clinic, St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.tandfonline.com/doi/full/10.1080/15284336.2016.1271503</url>
    <description>Journal article</description>
  </link>
  <results_reference>
    <citation>Harris M, Ganase B, Watson B, Hull MW, Guillemi SA, Zhang W, Saeedi R, Harrigan PR. Efficacy and safety of &quot;unboosting&quot; atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF. HIV Clin Trials. 2017 Jan;18(1):39-47. doi: 10.1080/15284336.2016.1271503. Epub 2017 Jan 9.</citation>
    <PMID>28067119</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>May 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2011</study_first_posted>
  <results_first_submitted>October 24, 2017</results_first_submitted>
  <results_first_submitted_qc>October 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2018</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Marianne Harris, MD</investigator_full_name>
    <investigator_title>Dr. Marianne Harris</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Switch</title>
          <description>switch to unboosted atazanavir 400mg daily with the same nucleoside (NRTI) backbone
atazanavir: switch to unboosted atazanavir 400 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Continuation</title>
          <description>continue on current regimen of atazanavir/ritonavir 300mg/100mg with the same nucleoside (NRTI) backbone
atazanavir/ritonavir: Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Switch</title>
          <description>Switch to atazanavir 400 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Continuation</title>
          <description>Remain on atazanavir/ritonavir 300mg/100 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="42" upper_limit="52"/>
                    <measurement group_id="B2" value="46" lower_limit="39" upper_limit="53"/>
                    <measurement group_id="B3" value="47" lower_limit="40" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportions of Subjects Experiencing Virologic Failure by Randomized Treatment Arm</title>
        <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart.</description>
        <time_frame>at or before 48 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Switch</title>
            <description>Switch to atazanavir 400 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Continuation</title>
            <description>Remain on atazanavir/ritonavir 300mg/100mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportions of Subjects Experiencing Virologic Failure by Randomized Treatment Arm</title>
          <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportions of Subjects in Each Randomized Treatment Arm With Atazanavir Trough Levels Below 150ng/mL</title>
        <description>Therapeutic drug monitoring (TDM) to determine atazanavir trough plasma level will be performed once on all subjects at 4-8 weeks</description>
        <time_frame>1 month (4-8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Switch</title>
            <description>Switch to atazanavir 400 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Continuation</title>
            <description>Remain on atazanavir/ritonavir 300mg/100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Proportions of Subjects in Each Randomized Treatment Arm With Atazanavir Trough Levels Below 150ng/mL</title>
          <description>Therapeutic drug monitoring (TDM) to determine atazanavir trough plasma level will be performed once on all subjects at 4-8 weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Experiencing Virologic Failure by Results of 1-month TDM</title>
        <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart. Comparison will be made between subjects with 1-month (4-8 week) on-study atazanavir trough levels &lt;150ng/mL and those with 1-month (4-8 week) on-study atazanavir trough levels &gt;150ng/mL.</description>
        <time_frame>at or before 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportions of Subjects Experiencing Virologic Failure by Randomized Treatment Arm</title>
        <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart.</description>
        <time_frame>at or before 24 weeks.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Experiencing Virologic Failure by Results of 1-month TDM</title>
        <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart. Comparison will be made between subjects with 1-month (4-8 week) on-study atazanavir trough levels &lt;150ng/mL and those with 1-month (4-8 week) on-study atazanavir trough levels &gt;150ng/mL.</description>
        <time_frame>at or before 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Cell Count Changes (Absolute and Fraction)</title>
        <description>Comparison will be made between randomized treatment arms.</description>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety (Clinical and Laboratory Adverse Events)</title>
        <description>Serious adverse events and discontinuations will be compared between randomized treatment arms</description>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Serum Bilirubin Levels</title>
        <description>Comparison will be made between randomized treatment arms.</description>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Parameters</title>
        <description>Comparison will be made between randomized treatment arms with respect to changes in fasting lipids and glucose, highly sensitive C-reactive protein [hsCRP], and apolipoprotein [apo]B, and proportions of subjects developing abnormalities or crossing predefined limits (e.g. NCEP thresholds for lipids)</description>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Assessed by MOS-HIV</title>
        <description>Changes in MOS-HIV scores from baseline will be compared between randomized treatment arms.</description>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Switch</title>
          <description>Switch to atazanavir 400 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Continuation</title>
          <description>Remain on atazanavir/ritonavir 300 mg/100 mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Marianne Harris</name_or_title>
      <organization>British Columbia Centre for Excellence in HIV/AIDS</organization>
      <phone>1-604-806-8771</phone>
      <email>mharris@cfenet.ubc.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

